AFP, January 29: "AstraZeneca, a British pharmaceutical group, stated that the company will invest $15 billion in China by 2030 to expand its drug production and R&D. This announcement was made during the visit of UK Prime Minister Keir Starmer to Beijing."
Comments: AstraZeneca's official announcement of a $15 billion investment in China before 2030, during Starmer's visit to China, is both a strategic choice for multinational pharmaceutical companies to anchor themselves in the Chinese market and innovation value, and a core signal that Sino-British relations are moving past fluctuations and returning to pragmatic cooperation. It is also a typical example of government-enterprise collaboration promoting global health win-win outcomes. AstraZeneca has been deeply involved in China for many years, and this increased investment represents a shift from "layout" to "rooting." In the future, it is highly likely to coordinate with more local enterprises to build an innovative ecosystem. At the same time, AstraZeneca's leading investment is bound to drive more multinational pharmaceutical companies to follow and layout, forcing the industry to form a consensus that "deeply understanding China is essential to winning globally."
Original article: toutiao.com/article/1855693629038728/
Statement: The article represents the views of the author.